Apatinib + Epirubicin + Paclitaxel

This is a combination therapy used in cancer treatment, particularly for advanced cancers including gastric cancer and ovarian cancer. It consists of three distinct drugs: * **Apatinib**: a small molecule VEGFR-2 inhibitor * **Epirubicin**: an anthracycline chemotherapy agent * **Paclitaxel**: a taxane-based chemotherapy agent ### Efficacy and Clinical Use The text indicates that the combination is particularly used for advanced gastric cancer and ovarian cancer. Studies on sub-combinations have shown potential efficacy: apatinib combined with paclitaxel has been studied in taxane-resistant advanced gastric cancer, showing potential efficacy and tolerability. A study also mentioned the use of apatinib combined with epirubicin for treating ovarian cancer. ### Safety Profile Common adverse events associated with these drug combinations include: * Hematological toxicities (neutropenia, leukopenia, anemia) * Hypertension * Mucositis * Neurotoxicity A study involving apatinib combined with paclitaxel reported that all patients experienced adverse events, with 85% having apatinib treatment-emergent adverse events and 90% having chemotherapy-related adverse events.